Please use this identifier to cite or link to this item:
|Title:||Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis|
|Citation:||Journal of Rheumatology, 2006; 33(10):1973-1979|
|Publisher:||J Rheumatol Publ Co|
|Leslie G. Cleland, Gillian E. Caughey, Michael J. James, and Susanna M. Proudman|
|Abstract:||<h4>Objective</h4>Rheumatoid arthritis (RA) is associated with increased risk for cardiovascular (CV) events through multiple factors. Fish oil has been shown to reduce symptoms in RA and to reduce CV risk. We assessed the effect of an antiinflammatory dose of fish oil on CV risk factors within a program of combination chemotherapy for patients with early RA.<h4>Methods</h4>Patients who chose not to take fish oil (n = 13) were compared with patients who achieved a sustained elevation of eicosapentaenoic acid (EPA) in plasma phospholipid fatty acids (> 5% total fatty acids) while taking fish oil over a 3-year period (n = 18). We examined cellular content of arachidonic acid (AA), synthesis of thromboxane A2 and prostaglandin E2, use of nonsteroidal antiinflammatory drugs (NSAID), traditional CV lipid risk factors, and disease activity at 3 years.<h4>Results</h4>At 3 years, AA (as a proportion of AA plus long-chain n-3 fatty acids that can compete with AA for cyclooxygenase metabolism) was 30% lower in platelets and 40% lower in peripheral blood mononuclear cells in subjects taking fish oil. Serum thromboxane B2 was 35% lower and lipopolysaccharide-stimulated whole-blood prostaglandin E2 was 41% lower with fish oil ingestion compared to no fish oil. NSAID use was reduced by 75% from baseline with fish oil (p < 0.05) and by 37% without fish oil (NS). Favorable changes in fasting blood lipids were seen with, but not without fish oil. Remission at 3 years was more frequent with fish oil use (72%) compared to no fish oil (31%).<h4>Conclusion</h4>Fish oil reduces cardiovascular risk in patients with RA through multiple mechanisms.|
|Keywords:||fish oil; early rheumatoid arthritis; combination therapy; cardiovascular risk; remission; cyclooxygenase inhibition|
|Description:||Copyright © 2006. All rights reserved.|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.